tbuckley/cabot-search huggingface dataset:
Better Outcomes for Lower Costs in Breast Cancer Care
Authors: Lee N. Newcomer
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Significant Engraftment of Immature Hematopoietic Cells From Patients with Low Risk Myelodysplastic Syndromes (MDS) in Immunodeficient Mice
Authors: Hind Medyouf, Florian Nolte, Maximilian Mossner, Verena Nowak, Bettina Zens, Katja Müdder, Julia Obländer, Stephanie Fey, Marion Klaumuenzer, Alice Fabarius, Eva Riedl, Alexander Marx, Henning Roehl, Nadine Mueller, Georgia Metzgeroth, Gero Huetter, Wolf-Karsten Hofmann, Andreas Trumpp, Daniel Nowak
Journal: Blood (2012)
Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.
Authors: Laurie H. Sehn, Jane Donaldson, Allison Filewich, Catherine Fitzgerald, Karamjit K. Gill, Nancy Runzer, Barb Searle, Sheila Souliere, John J. Spinelli, Judy Sutherland, Joseph M. Connors
Journal: Blood (2004)
3D printed complex tissue construct using stem cell-laden decellularized extracellular matrix bioinks for cardiac repair
Authors: Jinah Jang, Hun-Jun Park, Seok-Won Kim, Heejin Kim, Ju Young Park, Soo Jin Na, Hyeon Ji Kim, Moon Nyeo Park, Seung Hyun Choi, Sun Hwa Park, Sung Won Kim, Sang-Mo Kwon, Pum-Joon Kim, Dong-Woo Cho
Journal: Biomaterials (2016)
The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with Imatinib Plasma Levels.
Authors: Ai Leen Ang, Zhen Ping Wang, Li Yi Yang, Vallalan Natesan, Michelle Poon, Liang Piu Koh, Yeow Tee Goh, Balram Chowbay, Charles Chuah
Journal: Blood (2008)
Nasal chondrocyte-based engineered autologous cartilage tissue for repair of articular cartilage defects: an observational first-in-human trial
Authors: Marcus Mumme, Andrea Barbero, Sylvie Miot, Anke Wixmerten, Sandra Feliciano, Francine Wolf, Adelaide M Asnaghi, Daniel Baumhoer, Oliver Bieri, Martin Kretzschmar, Geert Pagenstert, Martin Haug, Dirk J Schaefer, Ivan Martin, Marcel Jakob
Journal: The Lancet (2016)
IgG4-Related Renal Lesions Detected by Delayed 18F-FDG PET/CT Scan
Authors: Zhanli Fu, Meng Liu, Jin Zhang, Ziao Li, Qian Li
Journal: Clinical Nuclear Medicine (2016)

Multiple renal lesions, which showed clearly demarcated low densities on contrast-enhanced CT, were revealed in a 56-year-old woman. The 18F-FDG avidity of the renal lesions was equal to or mildly higher than that of the renal cortex on the routine PET/CT scan, but significantly higher on the delayed scan. IgG4-related disease with renal involvement was confirmed subsequently by the measurement of serous IgG4 and the pathology of renal lesion.
Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) and amrubicin (AMR) in non-small cell Lung Cancer (NSCLC)
Authors: N. Masuda, T. Yanaihara, S. Onoda, M. Yamamoto, S. Ryuge, S. Hagiri, M. Wada, E. Kato, H. Mitsufuji, N. Yanase
Journal: Journal of Clinical Oncology (2005)

2070 Background: CPT-11 (topoisomerase I inhibitor) and AMR (topoisomerase II inhibitor) are active against several solid tumors including NSCLC. Based on the preclinical data, this phase I trial was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), anti-tumor activity, and PK assessments of this combination. Methods: Previously untreated patients (Pts) with stage IIIB/IV disease were treated with AMR iv, days 1–3 with a fixed dose of CPT-11 (60 mg/m2 iv, days 1 and 8) every 3 weeks (wks). The starting dose of AMR was 25 mg/m2. Three pts were treated at each dose level, with expansion to 6 pts in the event of DLT. Results: Eight pts were enrolled: 4 males, 4 females; median age was 61 years (range, 46–63). No pt had DLT at the first dose level. The MTD was reached at the second cohort (AMR 30 mg/m2): 3 DLTs were observed in 5 pts, which consisted of diarrhea (1 pt) and more than 1 wk delay for WBC recovery (2 pts). No significant interactions on the plasma pharmacokinetics between AMR, its active metabolite 13 OH-AMR, CPT-11, SN-38 and SN-38 glucuronide (G) were observed. There were 3 partial responses (37.5%). Conclusion: The recommended dose with this schedule is 60 mg/m2 of CPT-11, days 1 and 8, and 25 mg/m2 of AMR, days 1–3 every 3 wks. No significant financial relationships to disclose.
Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.
Authors: Tsila Zuckerman, Tamar Katz, Nuhad Haddad, Riva Fineman, Irit Avivi, Eldad J. Dann, Dvora Sahar, Ana Oliven, Ety Hertz, Yishay Ofran, Luiza Akria, Michal Markovitz, Tal Faibish, Jacob M. Rowe
Journal: Blood (2006)
Repurposing Drugs to Treat Zika
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
Authors: S Manier, J T Powers, A Sacco, S V Glavey, D Huynh, M R Reagan, K Z Salem, M Moschetta, J Shi, Y Mishima, C Roche-Lestienne, X Leleu, A M Roccaro, G Q Daley, I M Ghobrial
Journal: Leukemia (2016)
NICE proposes faster process to appraise cheaper drugs
Authors: Susan Mayor
Journal: BMJ (2016)

The National Institute for Health and Care Excellence (NICE) has announced proposals for a “fast track” appraisal process for drugs and other health technologies that offer “exceptional” value for money, together with clearer guidance on automatic NHS funding for any treatments it approves for very rare conditions.1

The proposals, which are part of a joint consultation by NICE and NHS England, would mean that treatments likely to have a cost per quality adjusted life year (QALY) of less than £10 000 (€11 065; $12 160) would be assessed using a …
CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm/RNP
Authors: Chizuru Akatsu, Kenro Shinagawa, Nobutaka Numoto, Zhihong Liu, Ayse Konuskan Ucar, Mohammad Aslam, Shirly Phoon, Takahiro Adachi, Koji Furukawa, Nobutoshi Ito, Takeshi Tsubata
Journal: The Journal of Experimental Medicine (2016)

Toll-like receptor 7 (TLR7) plays an essential role in development of systemic lupus erythematosus by co-stimulating B cells reactive to the endogenous TLR7 ligand Sm/ribonucleoprotein (RNP), a crucial lupus self-antigen. However, how the TLR7-mediated autoimmune response is regulated is not yet known. In this study, we demonstrate that CD72, an inhibitory B cell co-receptor known to prevent development of lupus, recognizes Sm/RNP at the extracellular C-type lectin-like domain (CTLD) and specifically inhibits B cell response to Sm/RNP. Moreover, the CTLD of CD72c, a lupus-susceptible allele, binds to Sm/RNP less strongly than that of lupus-resistant CD72a. Reduced binding of CD72c is supported by x-ray crystallographic analysis that reveals a considerable alteration in charge at the putative ligand-binding site. Thus, CD72 appears to specifically inhibit B cell response to the endogenous TLR7 ligand Sm/RNP through CTLD-mediated recognition of Sm/RNP, thereby preventing production of anti-Sm/RNP antibody crucial for development of lupus.
Comparison between the causes of rejection to participate (RP) and screening failures (SF) in oncology clinical trials (OCT).
Authors: L. E. Fein, A. Romera, M. C. Micheri, M. I. Diaz, R. A. Sala
Journal: Journal of Clinical Oncology (2010)

6126 Background: OCT are the mainstay of new drug development for the treatment of cancer. Patient decision whether or not to participate is a complex process that may involve family members or other health care professionals. RP added to SF may result in an important reduction of recruitment potential of a given site. Methods: Retrospective analysis of recruitment and clinical records of patients offered to participate (including those that rejected to participate and the SF) between 2005 and 2009 (n=570). To identify the causes of RP. To compare the importance of RP versus SF as a limit to recruitment. Results: 302 women (53%), median age 59 years (range: 36 a 89). 82 patients (14,3%) rejected to participate. 146 patients (29,9 %) were SF. Conclusions: In our series 44% (RP: 14,3% SF: 29,9%) of candidate patients do not participate in an OCT due to their own decision or due to SF. SF impacts recruitment more than RP. Causes of rejection as the negative opinion of family members and physicians and prejudices about clinical trials could in the future be addressed with properly design programs. Causes of RP in OCT Total % Burden related with procedures—Distance 18 21.95 Preference of standard treatment/not interested 16 19.51 Negative opinion of a family member 13 15.85 Prejudices about clinical trials 13 15.85 Negative opinion of another physician 11 13.41 No record 7 8.54 Use of placebo 4 4.88 82 100.00 No significant financial relationships to disclose.
GW26-e4778 Constitutive Expression of IGF-1 in BMSCs Improves Migration, Attenuates Cardiomyocyte Apoptosis and Promotes Cardiac Function After Acute Myocardial Infarction in Rats.
Authors: Jia Xu, Ren Jiang, Hong Zhan, Ruibin Cai, Zi Ye, Yan Xiong
Journal: Journal of the American College of Cardiology (2015)
Insulin-Like Growth Factor–Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction
Authors: Parul U. Gandhi, Hanna K. Gaggin, Margaret M. Redfield, Horng H. Chen, Susanna R. Stevens, Kevin J. Anstrom, Marc J. Semigran, Peter Liu, James L. Januzzi
Journal: JACC Heart Failure (2016)
18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study
Authors: F. Di Fabio, C. Pinto, S. Fanti, F. L. Rojas Llimpe, C. Longobardi, C. Nanni, C. Funaioli, V. Ambrosini, F. Sperandi, A. A. Martoni
Journal: Journal of Clinical Oncology (2006)

4061 Background: The aim of the study was to evaluate 18FDG-PET impact in gastric or GEJ cancer patients (pts) treated with cetuximab plus chemotherapy. Methods: Pts with stomach or GEJ unresectable/metastatic adenocarcinoma, not yet treated, EGFR+, were enrolled in the FOLCETUX study. Pts received cetuximab weekly at 400 mg/m 2 iv loading dose, and then at 250 mg/m 2 iv maintenance dose, weekly at 400 mg/m 2 iv loading dose, and then at 250 mg/m 2 iv maintenance dose, CPT11 180 mg/m 2 iv d1, LFA 100 mg/m 2 iv followed by 5FU 400 mg/m 2 iv bolus and 600 mg/m 2 iv continuous infusion 22h d1–2 (FOLFIRI) every 2 weeks, for a maximum of 24 weeks, then cetuximab alone was allowed in pts with CR/PR/SD. Anti-tumor activity was assessed by CT and PET scan at baseline and then every 6 weeks. A decrease in tumor FDG-uptake (metabolic response) was evaluated according to EORTC recommendations; objective response (OR) was evaluated with CT scan according to the RECIST criteria. Results: From November 2004 to December 2005, 22 pts (16M, 6F) performed at least 2 consecutive PET scans (at baseline and after 6 weeks), with a total of 91 PET scans (median per pts 4; range 2–8). PET was positive in 20 pts (90.9%); no FDG uptake was seen in 2 pts (9.1%) with signet ring cell carcinoma. A metabolic response correctly predicted: CR/PR in 10/12 pts (83%) after 6 weeks of therapy and in 11/12 (91.7%) after 12 weeks; SD in 4/8 pts (50%) after both 6 and 12 weeks. On the whole, response to therapy was predicted by PET after 6 weeks in 14/20 pts (70%). No correlation was demonstrated between median Standardized Uptake Value (SUV) at baseline PET and OR: 10.9 (3–29) in CR/PR pts and 9.6 (6.4–29.8) in SD pts. In the PET scan after 6, 12 and 18 weeks, the median SUV value respectively decreased to 4.4, 2.6 and &lt;2.0 in CR/PR pts and to 7.5, 7.4 and 3.6 in SD pts. The percentage of SUV reduction after 6 weeks was 54.2 in CR/PR pts vs 30.3 in SD pts (p = 0.36); no difference was observed between intestina (55%) and non-intestinal (45%) subtypes. No significant correlation was observed between the Ki-67 and SUV value. Conclusions: These preliminary results suggest that PET can make an early prediction of the response to cetuximab plus FOLFIRI therapy. No significant financial relationships to disclose.
Mini-Autologous Hematopoietic Stem Cell Transplantations as a New Treatment Modality for Multiple Sclerosis Patients
Authors: Andrei A Novik, Vladimir Y Melnichenko, Denis A Fedorenko, Ruslana V Kruglina, Tatiana I Ionova, Anton V Kishtovich, Roman I Ivanov, Gary J Gorodokin
Journal: Blood (2008)
A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome
Authors: Worawan B. Limpitikul, Ivy E. Dick, David J. Tester, Nicole J. Boczek, Pattraranee Limphong, Wanjun Yang, Myoung Hyun Choi, Jennifer Babich, Deborah DiSilvestre, Ronald J. Kanter, Gordon F. Tomaselli, Michael J. Ackerman, David T. Yue
Journal: Circulation Research (2016)

Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca2+/calmodulin (CaM)-dependent inactivation of L-type Ca2+ channels.To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS.We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca2+ cycling properties, and (3) diminished Ca2+/CaM-dependent inactivation of L-type Ca2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca2+/CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy.Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.
Frequency and Intensity of Antibody Responses to Antigens Encoded by KDM5D (SMCY) and Other H-Y Genes After Allogeneic Hematopoietic Cell Transplantation,
Authors: Takakazu Kawase, Nathan D. Ord, Andrea Towlerton, Shoko Satoh, Tara Bumgarner, Mary E.D. Flowers, Stephanie J. Lee, Paul J Martin, Stanley R. Riddell, John A. Hansen, David B Miklos, Edus H. Warren
Journal: Blood (2011)
Dysregulation of the TGF β Pathway in Induced Pluripotent Stem Cells (iPSCs) Generated from Patients with Diamond Blackfan Anemia (DBA)
Authors: Jingping Ge, Marisa Apicella, Jason A. Mills, Loic Garcon, Deborah L. French, Mitchell J. Weiss, Monica Bessler, Philip J Mason
Journal: Blood (2014)
Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience
Authors: David Sibon, Ana Berceanu, David Ghez, Frantz Foissac, Leila Kammoun, Thorsten Braun, Denis Caillot, Mario Ojeda-Uribe, Romain Guieze, Céline Berthon, Laurence Sanhes, Bérengère Gruson, Didier Bouscary, Christian Recher, Laure Stalnikiewicz, Philippe Rousselot, Emmanuel Raffoux, Thomas Prebet, Bruno Salles, Stéphane de Botton, Ambroise Marcais, Felipe Suarez, Olivier Hermine
Journal: Blood (2011)
Bone Marrow Involvement Detected By Ig Heavy Chain Rearrangement Has an Negative Impact of Progression Free Survival Independently of IPI and FDG-PET in Diffuse Large B-Cell Lymphoma
Authors: Yuichiro Ono, Daisuke Kato, Tomohiro Yabushita, Yoshimitsu Shimomura, Yusuke Koba, Yotaro Ochi, Nobuhiro Hiramoto, Satoshi Yoshioka, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Yukihiro Imai, Hayato Maruoka, Hisako Hashimoto, Takayuki Ishikawa
Journal: Blood (2015)
Long-term outcome of penile cancer: Single North American institutional study
Authors: N. Radhakrishnan, R. Roy, A. Thomas, B. Mehrotra, U. Iqbal
Journal: Journal of Clinical Oncology (2007)

15645 Background: Penile cancer is a rare malignancy in the Western world with limited published data. We conducted a review of patient (pt.) records diagnosed with penile cancer at our instituition to evaluate the patterns of treatment, responses, recurrences and long term outcomes. Methods: IRB approval was obtained for this retrospective analysis. Tumor registry data was analysed for all adult patients diagnosed with penile cancers between 1995 and 2005. Patient characteristics including age, disease stage, histology, grade, ethnicity, treatment modalities and outcomes were recorded. Results: 24 pts were identified. Median age: 68 years (range: 38 - 86), Stage distribution: Stage 0 (n=7, 29%), Stage I: n =8 (33.%) ; Stage II: n= 4 (17%); Stage III: n = 1 (4%), Stage IV: n=4 (16.7%); ethnicity: Caucasian:17, African-American: n=3; Hispanic: n=1;and South Asian: n=6; Histology: squamous (sq.): n = 21(88%), sq. with sarcomatoid features: n=1(4%), small cell ca: n = 1, (4%); poorly diff. ca: n = 1 (4%). Grades 1,2,3 in each stage respectively : stage I: ( n= 4, 2, 1), stage II: (n = 0,1,2), stage III: (1,0,0), stage IV: (n = 1,2,1). Treatment and Outcome: All pts with stage 0 disease were treated with excision biopsy. 3 of 7 (40%) recurred but are disease free after re-excision. All pts with Stage I disease were treated with partial penectomy. Two of 8 (25%) recurred, of which one pt died of his disease. All pts with stage II were treated with surgery (penectomy) and CT. One pt was additionally treated with RT to the groin. Except for this pt all stage II pts recurred and died due to recurrent disease. The pt with stage III disease was treated with a partial penectomy and CT and remains disease free without recurrence. All pts with stage IV disease were treated with CT, 3 were also treated with RT , but all died of metastatic disease. Median OS: Stage 0: 70+ mo, (20–150 ); Stage I: 69 mo (11–133); Stage II: 25 mo(12–84); Stage III: 25 mo; Stage IV: 7 mo ( 7- 23); Conclusions: Pts with early stage 0 and I disease have a high local recurrence rate (33%) but are curable with surgical salvage. Stages II, III and IV pts have high recurrence rates and poor prognoses despite treatment with penectomy and CT. Future trials should address the benefit of adjuvant chemo/RT in patients with intermediate stage (II &amp; III) disease. No significant financial relationships to disclose.
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study.
Authors: Giovanna Meloni, Simona Iacobelli, Paola Fazi, Marco Vignetti, Francesco Di Raimondo, Felicetto Ferrara, Vincenzo Liso, Salvatore Mirto, Giuseppe Fioritoni, Alessandra Tedeschi, Giuseppe Torelli, Federica Sorà, Federico Mosna, Ciro Rinaldi, Francesco Nobile, Robert Foà, Franco Mandelli
Journal: Blood (2005)
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients
Authors: Charles Béguelin, Darius Moradpour, Roland Sahli, Franziska Suter-Riniker, Alexander Lüthi, Matthias Cavassini, Huldrych F. Günthard, Manuel Battegay, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Dominique L. Braun, Hansjakob Furrer, Andri Rauch, Gilles Wandeler
Journal: Journal of Hepatology (2016)
Diagnosis of Deep Vein Thrombosis (DVT) In Critically Ill Patients
Authors: Arino Yaguchi, Ryuichi Moroi, Tomoyuki Harada, Munekazu Takeda, Masaru Abe, Mizuho Namiki, Keiko Natori, Noriko Saito, Reon Nagai, Taijiro Goto, Hideaki Suzuki, Toshiko Motoji
Journal: Blood (2010)
Early Gadolinium Enhancement for Determination of Area at Risk
Authors: Sophia Hammer-Hansen, Steve W. Leung, Li-Yueh Hsu, Joel R. Wilson, Joni Taylor, Anders M. Greve, Jens Jakob Thune, Lars Køber, Peter Kellman, Andrew E. Arai
Journal: JACC. Cardiovascular imaging (2016)

The aim of this study was to determine whether early gadolinium enhancement (EGE) by cardiac magnetic resonance (CMR) in a canine model of reperfused myocardial infarction depicts the area at risk (AAR) as determined by microsphere blood flow analysis.
Successful Reduced-Intensity Stem Cell Transplantation From Unrelated Cord Blood In Three Patients with X-Linked Severe Combined Immunodeficiency.
Authors: Akihiro Iguchi, Mizuho Ichikawa, Nobuaki Kawamura, Shunichiro Takezaki, Yuka Okura, Jun Inamoto, Junjiro Ohshima, Tomonobu Sato, Masahide Nakajima, Makoto Kaneda, Yuko Cho, Masafumi Yamada, Ryoji Kobayashi, Ichiro Kobayashi, Tadashi Ariga
Journal: Blood (2010)